World Scan Project, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that World Scan Project, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $25.21M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $288.1K | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $14.52M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $11.81M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $4.95M | May 10, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $7.61M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $30.85M | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $18.12M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $6.79M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $3.27M | May 10, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | ($768.4K) | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | ($3.42M) | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $8.91M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $2.33M | Feb 10, 2023 |
| FY2020 | Dec 31, 2020 | $1.31M | Feb 23, 2021 |
| FY2021 | Oct 31, 2020 | $1.31M | May 10, 2022 |
| FY2020 | Oct 31, 2019 | ($189) | Feb 23, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Oct 31, 2020 | $2.03M | Feb 23, 2021 |
| FY2020 | Oct 31, 2019 | ($189) | Feb 23, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Oct 31, 2023 | $18.72M | Nov 19, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | ($16.86M) | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | ($170.5K) | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $4.61M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $2.03M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $568.8K | May 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $27.41M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $14.04M | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $25.50M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $6.49M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $2.40M | May 10, 2022 |
| FY2020 | Oct 31, 2019 | $0 | Feb 23, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $10.83M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $5.32M | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $14.90M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $2.67M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $681.6K | May 10, 2022 |
| FY2020 | Oct 31, 2019 | $189 | Feb 23, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 31, 2022 | $10.60M | Feb 10, 2023 |
| FY2022 | Oct 31, 2021 | $3.81M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $1.72M | May 10, 2022 |
| FY2020 | Oct 31, 2019 | ($189) | Feb 23, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $8.37M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $9.14M | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | $12.56M | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | $3.65M | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | $1.31M | May 10, 2022 |
| FY2020 | Oct 31, 2019 | ($189) | Feb 23, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $1.63M | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | $5.70M | Sep 2, 2025 |
| FY2024 | Oct 31, 2022 | $5.84M | Sep 2, 2025 |
| FY2023 | Oct 31, 2021 | $2.58M | Nov 19, 2024 |
| FY2022 | Oct 31, 2020 | $974.6K | Feb 10, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | 0 | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | 0 | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | 0 | May 10, 2022 |
| FY2020 | Oct 31, 2019 | 0 | Feb 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | 0 | Sep 2, 2025 |
| FY2024 | Oct 31, 2023 | 0 | Sep 2, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Nov 19, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Feb 10, 2023 |
| FY2021 | Oct 31, 2020 | 0 | May 10, 2022 |
| FY2020 | Oct 31, 2019 | 0 | Feb 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Feb 10, 2023 | 10.65M | Feb 10, 2023 |
| FY2020 | Oct 31, 2020 | 10.65M | Feb 23, 2021 |
| FY2020 | Oct 31, 2019 | 10.00M | Feb 23, 2021 |